Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-Clear: Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B
NCT04449029Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2020
- Primary completion
- Mar 2022
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 22
01
Overview
A Phase 2 trial of bepirovirsen in Chronic Hepatitis B (CHB), sponsored by GSK. Started Jul 2020; status: completed.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04449029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04449029.